CHRISTINA INCLAN: Open Payments
NPI 1336454909 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,269 in 36 payments from 10 companies in 2025. Trend: 2023 $1,481 · 2024 $3,156 · 2025 $1,269
Food & beverage: $1,269
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 6 | $541 |
| ABBVIE INC. | 13 | $301 |
| Otsuka America Pharmaceutical, Inc. | 3 | $150 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $141 |
| Bausch Health US, LLC | 2 | $44 |
| E.R. Squibb & Sons, L.L.C. | 1 | $26 |
| Almatica Pharma LLC | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Validus Pharmaceuticals LLC | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
Products named: UZEDY, VRAYLAR, CAPLYTA, REXULTI, APLENZIN, ABILIFY ASIMTUFII, COBENFY, LOREEV XR.
Industry payments across TX — which companies pay providers there.
